The kras mutation percentage in mcrc is over 50 percent of the 32 or so in the poster. (Or they specifically highlighting that fact for a reason or is just a common thing to note that?)
I was wondering what the kras mutation likelihood was or might have been in the 5 tnbc survivors.
"Low Mutation Frequency: While common in other cancers, somatic KRAS mutations are generally infrequent in TNBC, appearing in only about 2–5% of cases.
Late-Stage (3rd and 4th) Relevance: While mutations are rare, the KRAS gene is frequently amplified (seen in ~32% of cases) or overexpressed in metastatic or advanced TNBC, driving tumor aggression and resistance to therapy.
Metastatic Potential: Metastatic progression in TNBC often depends on KRAS-supported invasion.
Specific Subsets: A unique, inherited KRAS variant (rs61764370) has been found to be significantly enriched in premenopausal women with TNBC (21% of cases in some studies)."
I was wondering what the kras mutation likelihood was or might have been in the 5 tnbc survivors.
"Low Mutation Frequency: While common in other cancers, somatic KRAS mutations are generally infrequent in TNBC, appearing in only about 2–5% of cases.
Late-Stage (3rd and 4th) Relevance: While mutations are rare, the KRAS gene is frequently amplified (seen in ~32% of cases) or overexpressed in metastatic or advanced TNBC, driving tumor aggression and resistance to therapy.
Metastatic Potential: Metastatic progression in TNBC often depends on KRAS-supported invasion.
Specific Subsets: A unique, inherited KRAS variant (rs61764370) has been found to be significantly enriched in premenopausal women with TNBC (21% of cases in some studies)."
4